Degenerative diseases such as Alzheimer’s, Parkinson’s and cataracts are responsible for a significant proportion of global morbidity and mortality. There is currently no cure for these diseases, and the treatments available are palliative and have limited effectiveness.
The invention is a series of new hydrazones structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde. These hydrazones have the potential to act as protein aggregation modifying agents (MPACs), preventing and/or decreasing protein oligomerization, both amyloid and non-amyloid.
The proposed hydrazones bind to physiological metal ions, such as copper and zinc, which are essential for the formation of protein aggregates. The binding of hydrazones to these ions prevents their interaction with target peptides and proteins, which prevents the formation of such aggregates.
Patent title:
N-acylhydrazonic compounds, use in the treatment of amyloid and non-amyloid degenerative aggregopathies, and pharmaceutical composition
Deposit Number:
BR 10 2020 005423 6
Pontifical Catholic University of Rio de Janeiro – PUC-Rio
Rua Marquês de São Vicente, 225, Gávea
Rio de Janeiro, RJ – Brasil
Zip code: 22451-900
Postal box: 38097
Phone:
+55 (21) 3527-2155